Focused on developing innovative antiviral therapeutics, this biotech firm specializes in treatments for chronic hepatitis B virus (HBV) and other viral infections. Its pipeline includes core inhibitor candidates that target the viral replication process, attracting investor interest in its potential to address unmet medical needs in virology.
1 member of Congress has disclosed 2 trades in Assembly Biosciences, Inc. (ASMB), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-04 | Christopher L. Jacobs | sell | $1K – $15K |
| 2020-12-28 | Christopher L. Jacobs | buy | $1K – $15K |